Jaguar Health Dividend
Dividend criteria checks 0/6
Jaguar Health does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-388.1%
Buyback Yield
| Total Shareholder Yield | -388.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend updates
No updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if JAGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAGX's dividend payments have been increasing.
Dividend Yield vs Market
| Jaguar Health Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (JAGX) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.3% |
| Analyst forecast (JAGX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate JAGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JAGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate JAGX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as JAGX has not reported any payouts.